Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TELA Bio, Inc. (TELA : NSDQ)

• Company Description    TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices. TELA Bio Inc. is headquartered in Malvern, Pennsylvania. Number of Employees: 123

• Price / Volume Information    Yesterday's Closing Price: $8.89 Daily Weekly Monthly 20 Day Moving Average: 21,866 shares Shares Outstanding: 14.56 (millions) Market Capitalization: $129.42 (millions) Beta: 1.57 52 Week High: $16.53 52 Week Low: $7.23 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.49% 4.20% 12 Week -25.79% -18.41% Year To Date -30.55% -15.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 GREAT VALLEY PARKWAY SUITE 24 - MALVERN,PA 19355 USA ph: 484-320-2930 fax: - ir@telabio.com http://www.telabio.com

• General Corporate Information    Officers Antony Koblish - President; Chief Executive Officer and Director Doug Evans - Chairman; Board of Directors Roberto Cuca - Chief Operating Officer and Chief Financial Office Megan Smeykal - Chief Accounting Officer and Controller Kurt Azarbarzin - Director Peer Information TELA Bio, Inc. (CORR.) TELA Bio, Inc. (RSPI) TELA Bio, Inc. (CGXP) TELA Bio, Inc. (BGEN) TELA Bio, Inc. (GTBP) TELA Bio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 872381108 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 14.56 Most Recent Split Date: (:1) Beta: 1.57 Market Capitalization: $129.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.47 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.89 Price/Cash Flow: - Price / Sales: 4.07 EPS Growth vs. Year Ago Period: -33.93% vs. Previous Quarter: -27.12% Sales Growth vs. Year Ago Period: 40.05% vs. Previous Quarter: -1.71% ROE 03/31/22 - -155.13 12/31/21 - -106.93 09/30/21 - -84.60 ROA 03/31/22 - -55.28 12/31/21 - -46.96 09/30/21 - -42.22 Current Ratio 03/31/22 - 4.10 12/31/21 - 5.58 09/30/21 - 6.99 Quick Ratio 03/31/22 - 3.26 12/31/21 - 4.86 09/30/21 - 6.32 Operating Margin 03/31/22 - -113.15 12/31/21 - -112.94 09/30/21 - -121.27 Net Margin 03/31/22 - -113.15 12/31/21 - -112.94 09/30/21 - -121.27 Pre-Tax Margin 03/31/22 - -113.15 12/31/21 - -112.94 09/30/21 - -121.27 Book Value 03/31/22 - 0.69 12/31/21 - 1.39 09/30/21 - 1.92 Inventory Turnover 03/31/22 - 1.56 12/31/21 - 1.79 09/30/21 - 1.99 Debt-to-Equity 03/31/22 - 3.15 12/31/21 - 1.57 09/30/21 - 1.13 Debt-to-Capital 03/31/22 - 75.93 12/31/21 - 61.04 09/30/21 - 53.04

Powered by Zacks Investment Research ©